Conduct↦Safety↦Safety and Protective Measures↦Procedures
Was betrifft es? Warum ist das wichtig?
Safety and Protective Measures (SPM) are activities implemented without delay to ensure the protection of study participants including other involved persons against:
- Suspected new risks that may potentially jeopardize the safety of study participants (e.g. with a negative shift in the risk-benefit ratio of the study)
Based on safety concerns, the implementation of SPMs are required, and must be defined and documented both HRO, ClinO, and ClinO-MD studies. Reports should include a detailed description of the nature and circumstances that required the implementation of SPM.
SPM reporting requirements are based on the risk-category of the study, with category A studies reported to Swissmedic via the:
- Pharmacovigilance reporting system for IMP studies
- Materiovigilance reporting system for IMD studies
During study conduct, the SP-INV can decide to include a Data Safety Monitoring Board (DSMB). Based on safety risk review, the DSMB can provide support regarding the optimal implementation of SPM.
Was muss ich befolgen?
As a Project-Leader of an HRO research project, report any immediate SPMs to the Ethics Committee (EC) (via BASEC):
- Within 7 days, and describe:
- Circumstances that led to the implementation of SPM
- The nature of the SPMs
As a Site-INV of a ClinO or ClinO-MD study, report any immediate SPM and its root cause to:
- The SP-INV within 24 hours
- Ethics Committee (EC) via BASEC within:
- 7 days, for for Investigational Medicinal Product (IMP) studies
- 2 days, for in vitro diagnostic Investigational Medical Device (IMD) studies
As a SP-INV of a ClinO or ClinO-MD study, report any immediate SPM and its root cause to:
- Ethics Committee (EC) via BASEC, and
- Swissmedic for risk category B and C studies within:
- 7 days for IMP studies
- 2 days, for IMD studies
- 24 hours if the termination / interruption of an IMD study was due to safety reasons
Mehr
In the event of multi-centre EU or EEA studies, the SP-INV must also notify all other participating ECs within the same deadlines.
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
External Links
Swissethics – see in particular
- Templates and checklists / Notifications
Swissmedic – see in particular
- Human medicine
- Clinical trials on medicinal products
- Safety measures in clinical trials
- Medical devices
- Clinical trials
- Submissions during ongoing clinical trials
References
ISO 14155:2020 Medical device (access liable to cost) – see in particular section
- 3.46 Serious health threat
Swiss Law
ClinO – see in particular article
- Art. 37 Notification of safety and protective measures
ClinO-MD – see in particular article
- Art. 34 Reporting of safety and protective measures
HRO – see in particular article
- Art. 20 Notification of safety and protective measures